Brand assets
Download Nuletic brand assets for media use. Please use the logo as provided without modification.
Press & Media
Press kit, company facts, founder bio, and brand assets for journalists and media partners.
Nuleticis a physician-supervised biological optimization platform for men and women. Positioned as “The Digital Family Office for Biology,” Nuletic is designed to manage hormones, weight, cognition, and aging the way a family office manages wealth.
The platform will combine physician-supervised protocols (hormone therapy, GLP-1 weight management, peptide therapy) with AI-powered protocol optimization and continuous biomarker monitoring. Nuletic is designed to serve individuals, couples, and organizations.
Founded
2026
Headquarters
United States
Founder
Val Narodetsky
Stage
Pre-launch
Val Narodetsky is a Ukrainian-born serial entrepreneur who arrived in the United States in 1998. As CEO of Odesa.co, he connects American tech companies with elite Eastern European engineering talent. Val has built multiple companies from zero to acquisition.
Nuletic was born from Val's personal experience with biological optimization. At 40, he worked with physicians to build a comprehensive protocol combining hormone therapy, peptides, and metabolic optimization. The transformation was profound, but the experience of accessing care was fragmented and frustrating. Nuletic is the platform he wished existed.
Val is available for interviews on: the grey-market peptide collapse, the future of physician-supervised optimization, GLP-1 medications and accessibility, the “Digital Family Office for Biology” concept, and building health tech companies.
Contact: press@nuletic.com
Nuletic sits at the intersection of several trending stories. Journalists are welcome to use these angles and cite Nuletic's published research and guides.
Tens of thousands of people search each month for what happened to Peptide Sciences. Major grey-market vendors have shut down amid FDA enforcement, and many users are seeking legitimate access.
Read the full guide →Branded Wegovy carries a list price of about $1,349/month (Novo Nordisk, as of 2026), while compounded semaglutide has run roughly $150-300/month; compounded availability shifted after the FDA semaglutide shortage was resolved. The price gap continues to drive interest in compounding pharmacies and telehealth.
Read the full guide →There has been reporting and industry advocacy that some Category 2 peptides could be reclassified to Category 1 for legal compounding. No reclassification has been finalized; if it happened, it would change access for patients and providers. Verify current FDA status before acting.
Read the full guide →The large majority of women experience perimenopause and menopause symptoms (up to about 80% experience vasomotor symptoms, per The Menopause Society). Most are told it's 'just stress.' The gap between what medicine offers and what women need.
Read the full guide →Reference ranges designed for population averages leave millions of patients symptomatic but 'normal.' The optimization movement is the response.
Read the full guide →High-performance organizations are investing in biological optimization for their executives. Not yoga and fruit bowls. Hormones and biomarkers.
Read the full guide →Download Nuletic brand assets for media use. Please use the logo as provided without modification.
90+
Evidence-based guides
24
Peptide encyclopedia entries
250+
Cited research references
8
Health pillars covered
3
Interactive health tools
50+
Glossary terms defined
For press inquiries, interview requests, or media partnerships, contact us at:
press@nuletic.comWe typically respond within 24 hours.
Note: Nuletic is a pre-launch platform. Clinical services are not yet available. Content on nuletic.com is for informational purposes only and does not constitute medical advice.
